Medical Weight Loss in Kottayam — Ozempic, Wegovy & Mounjaro

Medical weight loss targets the neuroendocrine drivers of obesity — not just caloric intake. When you diet, your hypothalamus increases ghrelin (hunger hormone) and decreases leptin (satiety hormone), creating biological pressure to regain weight. GLP-1 receptor agonists like semaglutide and tirzepatide override this hormonal resistance by mimicking incretin hormones that signal fullness and improve insulin sensitivity. The STEP 1 trial demonstrated 14.9% weight loss with semaglutide 2.4 mg versus 2.4% with placebo over 68 weeks — a difference no behavioural intervention alone has matched.

Three FDA-approved options: Ozempic (semaglutide 0.25–1 mg weekly, primarily for Type 2 diabetes with weight loss benefit), Wegovy (semaglutide 2.4 mg weekly, specifically approved for weight management — available in India since June 2025), and Mounjaro (tirzepatide 2.5–15 mg weekly, dual GIP/GLP-1 agonist with highest efficacy data). Dr. Sarath Chandran selects based on your HbA1c, BMI, comorbidity profile, and prior medication history. Dose titration follows a 4-week escalation schedule to minimise gastrointestinal side effects.

Approximate monthly medication costs in India (2026): Ozempic ₹8,000–12,000; Wegovy ₹18,000–25,000; Mounjaro ₹12,000–24,000 depending on dose level; Saxenda (liraglutide, daily injection) ₹8,000–12,000. Consultation fee starts at ₹300. These are indicative ranges — actual cost depends on prescribed dose, supply availability, and titration schedule. WhatsApp +91 8129883331 for a personalised cost estimate after initial evaluation.

Yes — and you should. The SuperHuman Program restructures Kerala cuisine rather than replacing it. Puttu is modified with ragi or millet flour instead of white rice flour. Appam batter is protein-enriched. Kanji uses a millet base. Sambar dal portions are doubled for protein. Coconut milk is measured, not eliminated. Fish curry and egg preparations remain central — they provide the 1.2–1.6 g/kg daily protein target essential for muscle preservation during fat loss. The goal is sustainable dietary restructuring, not temporary deprivation.

In the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), tirzepatide 15 mg achieved 22.5% mean body weight reduction versus approximately 15-17% with semaglutide 2.4 mg in STEP trials. The difference is attributable to tirzepatide's dual mechanism: it activates both GIP and GLP-1 receptors simultaneously, improving insulin sensitivity through two independent pathways. However, the optimal medication depends on individual factors — cost tolerance, gastrointestinal sensitivity, diabetes status, and HbA1c levels. Some patients respond better to semaglutide.

PCOS weight gain is fundamentally an insulin resistance problem — and GLP-1 agonists directly improve insulin sensitivity independent of their weight loss effect. Multiple studies show semaglutide reduces androgens and improves menstrual regularity in PCOS patients. Tirzepatide's additional GIP receptor activation provides even stronger insulin sensitisation. DermaVue Kottayam sees strong outcomes in PCOS patients, particularly when GLP-1 therapy is combined with the structured nutrition and exercise pillars of the SuperHuman Program.

Monthly visits include: weight and body composition analysis (bioimpedance — tracking fat mass vs lean mass separately), waist circumference, blood pressure, and symptom review. Quarterly blood work monitors fasting glucose, HbA1c, lipid panel, liver enzymes (ALT/AST), renal function (creatinine/eGFR), thyroid function, vitamin D, B12, and iron stores. This monitoring detects nutritional deficiency, hepatic steatosis improvement, and metabolic syndrome reversal — providing objective evidence beyond scale weight.

The most common side effects are gastrointestinal: nausea (30-40% of patients during titration), reduced appetite, and occasional vomiting — these typically resolve within 4-6 weeks as the body adjusts. Constipation occurs in approximately 15% of patients. Less common: injection site reactions, headache, mild fatigue. Serious but rare: pancreatitis (contraindicated in patients with history), gallbladder disease. DermaVue Kottayam screens for personal and family history of medullary thyroid carcinoma, pancreatitis, and MEN2 syndrome before prescribing. Slow-dose titration — starting at the lowest dose and escalating every 4 weeks — minimises side effects substantially.

Kottayam's 67-87% humidity and 3,094 mm annual rainfall make outdoor exercise inconsistent, particularly during monsoon months (June-September). The SuperHuman Program prescribes 2-3 weekly resistance training sessions using indoor-compatible protocols — compound movements (squats, deadlifts, rows, presses) that maximise muscle protein synthesis per session. Morning sessions before 8 AM are recommended during humid months. Resistance training is non-negotiable: without it, up to 40% of weight lost can be lean mass, reducing resting metabolic rate and increasing regain risk.

WhatsApp +91 8129883331. Walk in to Zion Tower, 2nd Floor, Thellakom, near Caritas Matha Hospital on MC Road, Kottayam. The initial consultation (₹300) includes health history review, body composition analysis, metabolic risk screening, and personalised treatment planning. Patients from Ettumanoor (20 min), Changanassery (35 min), Pala (45 min), and Vaikom (50 min) are seen regularly. Monday to Saturday 9 AM–7 PM; Sunday 10 AM–6 PM.